Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer.
Industry: Health Care
First Day Return: +23.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/03/2020 |
Offer Price | $4.75 |
Price Range $4.75 - $4.75 | |
Offer Shares (mm) | 1.2 |
Deal Size ($mm) | $6 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 11/24/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $6 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | East Setauket, NY, United States |
Founded | 2005 |
Employees at IPO | 4 |
Website www.lixte.com |